Search

everythinglearnresearchcommunity

for

Search:↓

New compounds may help treat prostate cancer by reducing cell growth.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Certain natural compounds called terpenes may help prevent prostate cancer.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.

Large prostates link to more hair loss.

Minoxidil increases calcium levels and kills prostate cancer cells independently of calcium.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

Anti-androgen drugs can treat conditions like prostate cancer and male pattern baldness by blocking effects of testosterone and DHT.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Finasteride reduces AML cell growth by inhibiting androgen receptors.

Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.